Please assess the completion status of the following clinical trial:

Trial Title: TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Healthy participants must be non-smokers, normal weight, normal ECG, healthy on the basis of a medical evaluation, physical examination, medical history, ECG, vital signs, and laboratory results~* HCV patients must be of normal weight, normal ECG, chronic genotype 1 HCV infection, non-responders or relapsers to previous treatment regimens and have a HCV viral load at least 50000 IU/mL plasma at screening.~Exclusion Criteria:~* Patients with history of cardiac disease, HIV-1 or HIV-2 test~* Women of childbearing potential~* History or evidence of abuse of alcohol, barbiturate, amphetamine, recreational or narcotic drug use, hepatitis A, B or C infection~* Positive urine drug test~* Any active or underlying disease~* History of drug allergy or hypersensitivity~* Participation in an investigational trial within 30 days prior to the first intake of study medication~* Recent donation of blood~* Abnormal laboratory values~* HCV patients with cardiac disease, co-infections with HIV-1, HIV-2 or liver infection other than HCV~* Women of childbearing potential~* Participants not agreeing to use a reliable birth control method until last trial visit~* Drug abuse~* Cardiovascular, hepatic or renal disease, diabetes, epilepsy, skin or psychiatric disease~* Enrolled in another clinical trial for 90 days prior to screening~* Evidence of Child Pugh B or C liver disease~* Having received a polymerase or protease inhibitor treatment during the last 6 months~* Abnormal laboratory values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).